SG11201810687SA - Serum albumin-binding fibronectin type iii domains - Google Patents
Serum albumin-binding fibronectin type iii domainsInfo
- Publication number
- SG11201810687SA SG11201810687SA SG11201810687SA SG11201810687SA SG11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA SG 11201810687S A SG11201810687S A SG 11201810687SA
- Authority
- SG
- Singapore
- Prior art keywords
- domains
- international
- serum albumin
- johnson
- rule
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title abstract 4
- 108010071390 Serum Albumin Proteins 0.000 title abstract 4
- 102000002090 Fibronectin type III Human genes 0.000 title abstract 3
- 108050009401 Fibronectin type III Proteins 0.000 title abstract 3
- 210000002966 serum Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
- G01N2333/765—Serum albumin, e.g. HSA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345190P | 2016-06-03 | 2016-06-03 | |
| PCT/US2017/035442 WO2017210425A1 (en) | 2016-06-03 | 2017-06-01 | Serum albumin-binding fibronectin type iii domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810687SA true SG11201810687SA (en) | 2018-12-28 |
Family
ID=60477987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810687SA SG11201810687SA (en) | 2016-06-03 | 2017-06-01 | Serum albumin-binding fibronectin type iii domains |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10925932B2 (ko) |
| EP (1) | EP3463430A4 (ko) |
| JP (2) | JP7111627B2 (ko) |
| KR (1) | KR102461666B1 (ko) |
| CN (1) | CN109562146A (ko) |
| AU (1) | AU2017273743B2 (ko) |
| EA (1) | EA201892796A1 (ko) |
| IL (2) | IL263347B (ko) |
| MA (1) | MA45186A (ko) |
| MX (1) | MX2018014876A (ko) |
| SG (1) | SG11201810687SA (ko) |
| UA (1) | UA126021C2 (ko) |
| WO (1) | WO2017210425A1 (ko) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899226B (zh) | 2013-10-14 | 2020-05-12 | 詹森生物科技公司 | 半胱氨酸工程化iii型纤连蛋白域结合分子 |
| SG11201810687SA (en) * | 2016-06-03 | 2018-12-28 | Janssen Biotech Inc | Serum albumin-binding fibronectin type iii domains |
| AU2017281083B2 (en) * | 2016-06-21 | 2022-01-27 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
| JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
| CN110724198B (zh) * | 2018-07-17 | 2023-05-26 | 上海一宸医药科技有限公司 | 长效纤连蛋白iii型结构域融合蛋白 |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
| USD1021702S1 (en) * | 2021-10-20 | 2024-04-09 | GM Global Technology Operations LLC | Vehicle center grille |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| GB8516415D0 (en) * | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) * | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU632065B2 (en) * | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) * | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| ATE168416T1 (de) * | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| PT1024191E (pt) * | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| PL174721B1 (pl) * | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| DK0985039T3 (da) * | 1997-06-12 | 2008-06-09 | Novartis Int Pharm Ltd | Kunstige antistof-polypeptider |
| ATE352559T1 (de) * | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| WO2001045746A2 (en) * | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20130226834A1 (en) | 2000-04-27 | 2013-08-29 | Networth Services, Inc. | Systems and methods for determining the financial status of bonds |
| JP4602614B2 (ja) * | 2001-09-26 | 2010-12-22 | アイシン精機株式会社 | 自動車用ドア |
| JP2006512895A (ja) * | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
| KR101051245B1 (ko) * | 2002-09-06 | 2011-07-21 | 이소제니카 리미티드 | 시험관내 펩타이드 발현 라이브러리 |
| EP2231870A4 (en) * | 2007-12-19 | 2011-01-26 | Centocor Ortho Biotech Inc | SYNTHESIS PHAGE VECTORS FOR DESIGNING AND GENERATING A BANK OF PROTEIN PHAGES OR PEPTIDES HUMAN NON-ANTIBODIES BY MELTING AT PIX OF PHAGE M13 |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| PL2356269T3 (pl) * | 2008-10-31 | 2016-12-30 | Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania | |
| DK2396011T3 (en) * | 2009-02-12 | 2016-04-25 | Janssen Biotech Inc | Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES |
| EP3569256B1 (en) | 2010-04-30 | 2022-06-15 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
| TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
| US9562089B2 (en) * | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| BR112014007469B1 (pt) * | 2011-09-27 | 2022-06-14 | Janssen Biotech, Inc | Método de fabricação de uma biblioteca de domínios de módulo de fibronectina tipo iii (fn3), biblioteca e método para obter um arcabouço de proteína |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| EP3080161B1 (en) * | 2013-12-09 | 2021-03-24 | New York University | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| JP6591437B2 (ja) * | 2014-03-20 | 2019-10-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 血清アルブミン結合フィブロネクチンｉｉｉ型ドメイン |
| WO2016197071A1 (en) * | 2015-06-05 | 2016-12-08 | New York University | Compositions and methods for anti-staphylococcal biologic agents |
| SG11201810687SA (en) * | 2016-06-03 | 2018-12-28 | Janssen Biotech Inc | Serum albumin-binding fibronectin type iii domains |
| AU2017281083B2 (en) * | 2016-06-21 | 2022-01-27 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
-
2017
- 2017-06-01 SG SG11201810687SA patent/SG11201810687SA/en unknown
- 2017-06-01 UA UAA201812826A patent/UA126021C2/uk unknown
- 2017-06-01 MA MA045186A patent/MA45186A/fr unknown
- 2017-06-01 JP JP2018562935A patent/JP7111627B2/ja active Active
- 2017-06-01 WO PCT/US2017/035442 patent/WO2017210425A1/en unknown
- 2017-06-01 CN CN201780047969.6A patent/CN109562146A/zh active Pending
- 2017-06-01 US US15/611,296 patent/US10925932B2/en active Active
- 2017-06-01 EA EA201892796A patent/EA201892796A1/ru unknown
- 2017-06-01 KR KR1020187037937A patent/KR102461666B1/ko active IP Right Grant
- 2017-06-01 EP EP17807478.7A patent/EP3463430A4/en active Pending
- 2017-06-01 AU AU2017273743A patent/AU2017273743B2/en active Active
- 2017-06-01 MX MX2018014876A patent/MX2018014876A/es unknown
-
2018
- 2018-11-28 IL IL263347A patent/IL263347B/en active IP Right Grant
-
2021
- 2021-01-20 US US17/153,229 patent/US11833190B2/en active Active
- 2021-05-05 IL IL282960A patent/IL282960B/en unknown
- 2021-12-08 JP JP2021199610A patent/JP2022046510A/ja not_active Withdrawn
-
2023
- 2023-10-27 US US18/496,397 patent/US20240100129A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017210425A1 (en) | 2017-12-07 |
| EA201892796A1 (ru) | 2019-06-28 |
| IL282960A (en) | 2021-06-30 |
| KR102461666B1 (ko) | 2022-11-01 |
| JP2019521662A (ja) | 2019-08-08 |
| UA126021C2 (uk) | 2022-08-03 |
| AU2017273743B2 (en) | 2021-12-02 |
| MX2018014876A (es) | 2019-05-22 |
| EP3463430A4 (en) | 2020-02-12 |
| EP3463430A1 (en) | 2019-04-10 |
| IL263347A (en) | 2018-12-31 |
| US20240100129A1 (en) | 2024-03-28 |
| US10925932B2 (en) | 2021-02-23 |
| US20170348397A1 (en) | 2017-12-07 |
| AU2017273743A1 (en) | 2019-01-03 |
| MA45186A (fr) | 2019-04-10 |
| CN109562146A (zh) | 2019-04-02 |
| KR20190013970A (ko) | 2019-02-11 |
| JP2022046510A (ja) | 2022-03-23 |
| IL282960B (en) | 2022-03-01 |
| IL263347B (en) | 2021-05-31 |
| US20210228688A1 (en) | 2021-07-29 |
| JP7111627B2 (ja) | 2022-08-02 |
| US11833190B2 (en) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810687SA (en) | Serum albumin-binding fibronectin type iii domains | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201901140QA (en) | Compounds and methods for reducing tau expression | |
| SG11201900744SA (en) | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them | |
| SG11201907209QA (en) | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | |
| SG11201907638QA (en) | Proteins binding cd33, nkg2d and cd16 | |
| SG11201811062XA (en) | Cysteine engineered fibronectin type iii domain binding molecules |